Kalshi has partnered with AppliedXL to introduce a new suite of prediction markets dedicated to clinical trial outcomes and FDA regulatory decisions. This initiative aims to provide accurate, publicly accessible probabilities that address the lack of transparency in drug development estimates, which typically remain confined to private entities. The markets will allow investors and stakeholders to act on specific drug assessments, independent of corporate overarching narratives. Contracts will reference established public documents to ensure transparent and reliable outcomes. Initial contracts include trials for AR1001 and approvals for Gilead/Arcellx’s anti-cancer treatment. The pilot phase emphasizes integrity and safety and will help refine market design based on user engagement.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://news.kalshi.com/p/kalshi-biotech-prediction-markets
